Novartis sees highest patent filings and grants during August in Q3 2023
Novartis saw the highest growth of 108% in patent filings in July and 146% in grants in August in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 108% and grants by 96%. GlobalData's DataBook provides a comprehensive analysis of Novartis's patent filings and grants. Buy the databook here. Novartis has been focused on protecting inventions in Japan(JP) with 109 publications in Q3 2023The Japan(JP) Patent Office dominates the patent filings and grants with nearly 21% filings and 18% grants. The Japan(JP), European Patent Office (E/P), United States(US), and China(CN) patent Office are among the top ten patent offices where Novartis is filings its patents. Among the top granted patent authorities, Novartis has 19% of its grants in United States(US), 18% in Japan(JP), and 10% in Canada(CA). Amgen could be the strongest competitor for NovartisIn terms of grant share, Novartis stands in two position among its competitors. Amgen and Johnson & Johnson secured the top positions according to recent patent publication data. Patents related to rare diseases and climate change lead Novartis's portfolioNovartis has the highest number of patents in rare diseases followed by, climate change and healthtech. For rare diseases, nearly 31% of patents were filed and 29% of patents were granted in Q3 2023. Ophthalmic devices related patents lead Novartis portfolio followed by leukemia, and multiple sclerosisNovartis has highest number of patents in ophthalmic devices followed by leukemia, multiple sclerosis, chronic obstructive pulmonary disease (copd) and asthma. For ophthalmic devices, nearly 4% of patents were filed and 5% of patents were granted in Q3 2023. For comprehensive analysis of Novartis's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for Novartis here.
What's Your Reaction?
